487 related articles for article (PubMed ID: 21844151)
1. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010.
Otten MH; Prince FH; Twilt M; Ten Cate R; Armbrust W; Hoppenreijs EP; Koopman-Keemink Y; Wulffraat NM; Gorter SL; Dolman KM; Swart JF; van den Berg JM; van Rossum MA; van Suijlekom-Smit LW
J Rheumatol; 2011 Oct; 38(10):2258-63. PubMed ID: 21844151
[TBL] [Abstract][Full Text] [Related]
2. Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children Register.
Anink J; Otten MH; Prince FH; Hoppenreijs EP; Wulffraat NM; Swart JF; ten Cate R; van Rossum MA; van den Berg JM; Dolman KM; Koopman-Keemink Y; Armbrust W; Kamphuis S; van Pelt PA; Gorter SL; van Suijlekom-Smit LW
Rheumatology (Oxford); 2013 Apr; 52(4):712-7. PubMed ID: 23267169
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register.
Otten MH; Prince FH; Anink J; Ten Cate R; Hoppenreijs EP; Armbrust W; Koopman-Keemink Y; van Pelt PA; Kamphuis S; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
Ann Rheum Dis; 2013 May; 72(5):721-7. PubMed ID: 22730374
[TBL] [Abstract][Full Text] [Related]
4. Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective?
Otten MH; Prince FH; Ten Cate R; van Rossum MA; Twilt M; Hoppenreijs EP; Koopman-Keemink Y; Oranje AP; de Waard-van der Spek FB; Gorter SL; Armbrust W; Dolman KM; Wulffraat NM; van Suijlekom-Smit LW
Ann Rheum Dis; 2011 Feb; 70(2):337-40. PubMed ID: 21068101
[TBL] [Abstract][Full Text] [Related]
5. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
Tynjälä P; Vähäsalo P; Honkanen V; Lahdenne P
Ann Rheum Dis; 2009 Apr; 68(4):552-7. PubMed ID: 18467515
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register.
Prince FH; Twilt M; ten Cate R; van Rossum MA; Armbrust W; Hoppenreijs EP; van Santen-Hoeufft M; Koopman-Keemink Y; Wulffraat NM; van Suijlekom-Smit LW
Ann Rheum Dis; 2009 May; 68(5):635-41. PubMed ID: 18413443
[TBL] [Abstract][Full Text] [Related]
7. Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?
Anink J; Otten MH; Gorter SL; Prince FH; van Rossum MA; van den Berg JM; van Pelt PA; Kamphuis S; Brinkman DM; Swen WA; Swart JF; Wulffraat NM; Dolman KM; Koopman-Keemink Y; Hoppenreijs EP; Armbrust W; ten Cate R; van Suijlekom-Smit LW
Rheumatology (Oxford); 2013 Sep; 52(9):1674-9. PubMed ID: 23740187
[TBL] [Abstract][Full Text] [Related]
8. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
Gerloni V; Pontikaki I; Gattinara M; Fantini F
Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
[TBL] [Abstract][Full Text] [Related]
9. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
[TBL] [Abstract][Full Text] [Related]
10. Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents.
Russo RA; Katsicas MM
J Rheumatol; 2009 May; 36(5):1078-82. PubMed ID: 19435972
[TBL] [Abstract][Full Text] [Related]
11. Experiences with tumour necrosis factor-{alpha} inhibitors in patients with juvenile idiopathic arthritis: Hungarian data from the National Institute of Rheumatology and Physiotherapy Registry.
Sevcic K; Orban I; Brodszky V; Bazso A; Balogh Z; Poor G; Kiss E
Rheumatology (Oxford); 2011 Jul; 50(7):1337-40. PubMed ID: 21372001
[TBL] [Abstract][Full Text] [Related]
12. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M;
Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes after withdrawal of anti-tumor necrosis factor α therapy in patients with juvenile idiopathic arthritis: a twelve-year experience.
Baszis K; Garbutt J; Toib D; Mao J; King A; White A; French A
Arthritis Rheum; 2011 Oct; 63(10):3163-8. PubMed ID: 21702011
[TBL] [Abstract][Full Text] [Related]
14. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis.
Tynjälä P; Lindahl P; Honkanen V; Lahdenne P; Kotaniemi K
Ann Rheum Dis; 2007 Apr; 66(4):548-50. PubMed ID: 17068061
[TBL] [Abstract][Full Text] [Related]
15. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
16. The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis.
Blom M; Kievit W; Fransen J; Kuper IH; den Broeder AA; De Gendt CM; Jansen TL; Brus HL; van de Laar MA; van Riel PL
J Rheumatol; 2009 Oct; 36(10):2171-7. PubMed ID: 19723902
[TBL] [Abstract][Full Text] [Related]
17. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry.
Atzeni F; Sarzi-Puttini P; Botsios C; Carletto A; Cipriani P; Favalli EG; Frati E; Foschi V; Gasparini S; Giardina A; Gremese E; Iannone F; Sebastiani M; Ziglioli T; Biasi D; Ferri C; Galeazzi M; Gerli R; Giacomelli R; Gorla R; Govoni M; Lapadula G; Marchesoni A; Salaffi F; Punzi L; Triolo G; Ferraccioli G
Autoimmun Rev; 2012 Dec; 12(2):225-9. PubMed ID: 22796281
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival.
Flouri I; Markatseli TE; Voulgari PV; Boki KA; Papadopoulos I; Settas L; Zisopoulos D; Skopouli FN; Iliopoulos A; Bertsias GK; Geborek P; Drosos AA; Boumpas DT; Sidiropoulos P
Semin Arthritis Rheum; 2014 Feb; 43(4):447-57. PubMed ID: 24012040
[TBL] [Abstract][Full Text] [Related]
19. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data.
Kievit W; Adang EM; Fransen J; Kuper HH; van de Laar MA; Jansen TL; De Gendt CM; De Rooij DJ; Brus HL; Van Oijen PC; Van Riel PC
Ann Rheum Dis; 2008 Sep; 67(9):1229-34. PubMed ID: 18174220
[TBL] [Abstract][Full Text] [Related]
20. Anaphylaxis to etanercept in two children with juvenile idiopathic arthritis.
Crayne CB; Gerhold K; Cron RQ
J Clin Rheumatol; 2013 Apr; 19(3):129-31. PubMed ID: 23519173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
